A new molecular construct (K1) has been developed to effectively deliver active drugs to heterogeneous tumor environments. K1 utilizes two cancer environment triggers (GSH and H2O2) for prodrug activation, releasing the active drug SN-38 under oxidative and reductive stress conditions in vitro. The construct specifically targets COX-2 positive colon cancer cells (SW620 and LoVo), demonstrating enhanced anticancer activity compared to SN-38 alone. This is due to the environmentally triggered drug release and simultaneous scavenging of intracellular redox stress species. K1 downregulates various cancer survival signaling pathways (AKT, p38, IL-6, VEGF, and TNF-α) while upregulating the anti-inflammatory response (IL-10). In vivo studies using a xenograft tumor regrowth model showed that K1 has improved therapeutic efficacy without noticeable systemic toxicity. This strategy offers a promising approach for treating solid tumors with intratumoral heterogeneity.-Scientific Journal cover by scapiens
[Scientific Journal cover design] Low-Thermal-Budget Fluorite-Structure Ferroelectrics for Future Electronic Device Applications
In article number 2100028, Jiyoung Kim, Si Joon Kim, and their team review key factors involved in developing fluorite-structure ferroelectrics
